SC 13G/A | 2019-10-09 | VENROCK ASSOCIATES V LP | CONSTELLATION PHARMACEUTICALS INC | 1,740,945 | 5.2% | EDGAR |
SC 13G/A | 2019-02-14 | Casdin Capital, LLC | CONSTELLATION PHARMACEUTICALS INC | 1,556,999 | 6.0% | EDGAR |
SC 13G/A | 2019-02-14 | Cormorant Asset Management, LP | CONSTELLATION PHARMACEUTICALS INC | 294,523 | - | EDGAR |
SC 13G | 2019-02-13 | FMR LLC | CONSTELLATION PHARMACEUTICALS INC | 1,574,445 | 6.1% | EDGAR |
SC 13G | 2019-02-13 | THIRD ROCK VENTURES LP | CONSTELLATION PHARMACEUTICALS INC | 3,034,083 | 11.8% | EDGAR |
SC 13G | 2019-02-13 | COLUMN GROUP L P | CONSTELLATION PHARMACEUTICALS INC | 2,584,957 | 10.0% | EDGAR |
SC 13G | 2018-10-31 | Casdin Capital, LLC | CONSTELLATION PHARMACEUTICALS INC | 1,512,986 | 5.9% | EDGAR |
SC 13G | 2018-08-02 | VENROCK ASSOCIATES V LP | CONSTELLATION PHARMACEUTICALS INC | 1,740,945 | 6.8% | EDGAR |
SC 13G | 2018-07-30 | Cormorant Asset Management, LP | CONSTELLATION PHARMACEUTICALS INC | 473,683 | - | EDGAR |
SC 13G | 2018-07-30 | Topspin Fund L.P. | CONSTELLATION PHARMACEUTICALS INC | 1,778,024 | 6.9% | EDGAR |
SC 13G | 2018-07-25 | REGENTS OF THE UNIVERSITY OF CALIFORNIA | CONSTELLATION PHARMACEUTICALS INC | 2,297,406 | 8.9% | EDGAR |
SC 13G | 2018-07-23 | Flynn James E | CONSTELLATION PHARMACEUTICALS INC | 835,843 | 3.2% | EDGAR |